High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin

Journal of the American College of Cardiology

Volumn 63, Issue 1, 2014, Pages 52-61

  Hijazi, Ziad ^a,b   Wallentin, Lars ^a,b   Siegbahn, Agneta ^a,b   Andersson, Ulrika ^a   Alexander, John H ^c   Atar, Dan ^d   Gersh, Bernard J ^e   Hanna, Michael ^f   Harjola, Veli Pekka ^g   Horowitz, John D ^h   Husted, Steen ⁱ   Hylek, Elaine M ^j   Lopes, Renato D ^c   McMurray, John J V ^k   Granger, Christopher B ^c  

^a UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e Mayo Clinic College of Medicine   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^j BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

atrial fibrillation; cardiac troponin; high sensitivity troponin T; risk stratification; stroke risk

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TROPONIN T; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; VASCULAR DISEASE;

AF; ATRIAL FIBRILLATION; CARDIAC TROPONIN; CI; CONFIDENCE INTERVAL; HAZARD RATIO; HIGH-SENSITIVITY TROPONIN T; HR; HS-TNT; IDI; INTEGRATED DISCRIMINATION IMPROVEMENT MEASURE; NET RECLASSIFICATION IMPROVEMENT; NRI; RISK STRATIFICATION; STROKE RISK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; STROKE; SURVIVAL RATE; TROPONIN T; UNITED STATES; WARFARIN;

EID: 84891818165     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.093     Document Type: Article

References (26)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
2. A.J. Camm, P. Kirchhof, and G.Y. Lip et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
3. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
4. C.B. Granger, J.H. Alexander, and J.J.V. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
5. B.F. Gage, A.D. Waterman, and W. Shannon et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
6. G.Y. Lip, R. Nieuwlaat, and R. Pisters et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
7. Z. Hijazi, J. Oldgren, and U. Andersson et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) substudy Circulation 125 2012 1605 1616
8. E. Giannitsis, K. Kurz, K. Hallermayer, J. Jarausch, A.S. Jaffe, and H.A. Katus Analytical validation of a high-sensitivity cardiac troponin T assay Clin Chem 56 2010 254 261
9. P. Venge, N. Johnston, B. Lindahl, and S. James Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia J Am Coll Cardiol 54 2009 1165 1172
10. J.A. de Lemos, M.H. Drazner, and T. Omland et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population JAMA 304 2010 2503 2512
11. C.R. deFilippi, J.A. de Lemos, and R.H. Christenson et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults JAMA 304 2010 2494 2502
12. J.L. Januzzi Jr., F. Bamberg, and H. Lee et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography Circulation 121 2010 1227 1234
13. R. Latini, S. Masson, and I.S. Anand et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure Circulation 116 2007 1242 1249
14. B. Lindahl, P. Venge, and S. James The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes Am Heart J 160 2010 224 229
15. T. Omland, J.A. de Lemos, and M.S. Sabatine et al. A sensitive cardiac troponin T assay in stable coronary artery disease N Engl J Med 361 2009 2538 2547
16. T. Reichlin, W. Hochholzer, and S. Bassetti et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays N Engl J Med 361 2009 858 867
17. R.D. Lopes, J.H. Alexander, and S.M. Al-Khatib et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
18. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
19. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
20. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Comments on 'integrated discrimination and net reclassification improvements - practical advice' Stat Med 27 2008 207 212
21. D. Dobrev, and S. Nattel Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics J Cardiovasc Pharmacol 52 2008 293 299
22. K.M. Eggers, L. Lind, and H. Ahlstrom et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects Eur Heart J 29 2008 2252 2258
23. A. Jeremias, and C.M. Gibson Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded Ann Intern Med 142 2005 786 791
24. B. Pirat, I. Atar, and C. Ertan et al. Comparison of C-reactive protein levels in patients who do and do not develop atrial fibrillation during electrophysiologic study Am J Cardiol 100 2007 1552 1555
25. H. Asakura, S. Hifumi, and H. Jokaji et al. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation Blood Coagul Fibrinolysis 3 1992 469 473
26. D.S. Conway, L.A. Pearce, B.S. Chin, R.G. Hart, and G.Y. Lip Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors Circulation 106 2002 1962 1967